BioPharmSignal logoBioPharmSignal

Biotech News

PMV Pharmaceuticals to Present Rezatapopt Pivotal Phase 2 Initial Analysis and Natural History Study Results at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

PMV Pharmaceuticals (PMVP)PMV PharmaceuticalsClinical readout

Oral presentation to highlight initial data from ongoing pivotal Phase 2 study of rezatapopt, a first-in-class precision oncology investigational therapy, in patients with advanced solid tumors harboring a TP53 Y220C mutation PRINCETON, N.J., Oct. 13, 2025 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals,

Related news

KYMRKymera2026-06-12 11:00 EST

Kymera Therapeutics Presents Phase 1 Data in Healthy Japanese Adults for KT-621, a First-in-Class Oral STAT6 Degrader, at the Japanese Dermatological Association Annual Meeting

KYMRKymera2026-06-09 11:00 EST

Kymera Therapeutics Announces First Participant Dosed in Phase 1 Trial of Oral IRAK4 Degrader, KT-485, and Milestone Achievement Under Sanofi Collaboration

LYELLyell Immunopharma2026-06-04 20:05 EST

Lyell Immunopharma to Present Phase 1/2 Safety and Translational Data for Ronde-Cel in Large B-Cell Lymphoma at the European Hematology Association 2026 Congress

FATEFate Therapeutics2026-08-14 11:00 EST

Fate Therapeutics Initiates Potentially Registrational RECLAIM-LN Clinical Trial of FT819 for the Treatment of Lupus Nephritis

ENTAEnanta Pharmaceuticals2026-06-18 11:00 EST

Enanta Pharmaceuticals Announces Advancement of its Zelicapavir Clinical Development Program for the Treatment of Respiratory Syncytial Virus (RSV)

PMVPPMV Pharmaceuticals2026-08-14 12:00 EST

PMV Pharmaceuticals Reports Second Quarter 2026 Financial Results and Corporate Highlights

EXELExelixis2026-06-22 12:00 EST

Exelixis Provides Update on the Phase 3 STELLAR-303 Trial Evaluating Zanzalintinib in Combination with an Immune Checkpoint Inhibitor in Patients with Metastatic Colorectal Cancer

COGTCogent Biosciences2026-06-12 12:00 EST

Cogent Biosciences Announces Detailed Data from APEX Pivotal Trial of Bezuclastinib in Patients with Advanced Systemic Mastocytosis at the 2026 European Hematology Association (EHA) Congress

LYELLyell Immunopharma2026-06-08 10:00 EST

Lyell Immunopharma Provides Update on Safety Profile of LYL273 in Relapsed or Refractory Metastatic Colorectal Cancer and Amends Phase 1 Trial to Phase 1/2 Expansion

RVMDRevolution Medicines2026-07-02 12:00 EST

Revolution Medicines Presents Phase 1/2 Clinical Data for Zoldonrasib Combination Regimens in Patients with RAS G12D Metastatic Pancreatic Cancer at ESMO Gastrointestinal Cancers Congress 2026

View all latest news

PMV Pharmaceuticals

Mutant-p53 Precision Oncology PMV Pharmaceuticals develops small-molecule precision therapies that target specific mutations in the p53 tumor-suppressor protein. Its platform is designed to restore the normal cancer-suppressing function of structurally altered p53 proteins, addressing mutations found across multiple solid-tumor...

Recent company news

PMVPPMV Pharmaceuticals2026-08-14 12:00 EST

PMV Pharmaceuticals Reports Second Quarter 2026 Financial Results and Corporate Highlights

PMVPPMV Pharmaceuticals2026-05-12 12:00 EST

PMV Pharmaceuticals Reports First Quarter 2026 Financial Results and Corporate Highlights

PMVPPMV Pharmaceuticals2026-04-22 12:00 EST

PMV Pharmaceuticals Announces Board Chair Transition

PMVPPMV Pharmaceuticals2026-03-06 13:00 EST

PMV Pharmaceuticals Reports Full Year 2025 Financial Results and Corporate Highlights

PMVPPMV Pharmaceuticals2026-02-26 13:00 EST

New England Journal of Medicine Publishes First-in-Human Rezatapopt Data Showing Selective Reactivation of Mutant p53 in Advanced Solid Tumors

Stock data

Close
1.33 USD
Market cap
62.93M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States